Timberlyne Therapeutics is a biopharmaceutical company developing novel therapies for autoimmune disorders, focusing on advancing a monoclonal antibody targeting CD38.

Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders.

Avenzo Therapeutics is a biotechnology company developing oncology therapies, including a CDK2 inhibitor for advanced solid tumors and HR+/HER2-negative metastatic breast cancer.

Lynk Pharmaceuticals is a clinical-stage company that specializes in the research and development of FIC and BIC drugs targeting autoimmune diseases, inflammation, and oncology, with a focus on developing second and third-generation JAK inhibitors.